Vascular heme oxygenase (HO) metabolizes heme to form carbon monoxide (CO). Increased heme-derived CO inhibits nitric oxide synthase and can contribute to hypertension via endothelial dysfunction in Dahl salt-sensitive rats. Obese Zucker rats (ZR) are models of metabolic syndrome. This study tests the hypothesis that endogenous CO formation is increased and contributes to hypertension and endothelial dysfunction in obese ZR. Awake obese ZR showed increased respiratory CO excretion which was lowered by HO inhibitor administration (ZnDPBG 25µmol/kg/24hr ip). In awake obese ZR, chronically instrumented with femoral arterial catheters, blood pressure was elevated and was decreased by the HO inhibitor, ZnDPBG.
Introduction
(2ml/kg/day 50mmol/l Na 2 CO 3 ip.) for three days for daily measurement of carbon monoxide excretion. Animals were placed in an acrylic airtight chamber with the outflow leading to a heated mercuric oxide bed coupled with a gas chromatograph (Peak, Mtn. View, CA) for the determination of carbon monoxide concentration, as has been detailed elsewhere (54,55). The chamber was continuously purged with purified air and the outflow sampled for carbon monoxide concentration at two minute intervals. After 10 minutes of equilibration, the average of four measurements were used to calculate the carbon monoxide excretion rate for the whole animal.
Metabolic Parameters Measurements and Tissue Extractions
On the day of the experiment, rats were weighed and anesthetized with thiobutabarbital (Inactin, 120mg/kg ip.) and a carotid arterial catheter was implanted for blood sample collections. Blood samples were drawn for immediate determination of non-fasting blood glucose (Accu-Chek Compact, Roche Diagnostics, Indianapolis, IN), glycated hemoglobin (HbA1c, DCA 2000+ analyzer, Bayer, Pittsburg, PA), and carboxyhemoglobin (HbCO) levels (OSM3 analyzer, Radiometer America, Inc., Westlake, OH), and lipid profile (Cardio Chek PA analyzer, QAS, Orlando, FL). Additional blood was collected in test tubes containing EDTA and plasma was collected by centrifugation. Plasma samples were aliquoted and stored at -20°C until Final Accepted Version R-00308-2005.R3 7 analyzed. Plasma insulin (rat insulin EIA kit, Cayman Chemical, Ann Arbor, MI) and oxidized LDL (competitive oxidized LDL ELISA kit, Mercodia Inc, Winston Salem, NC) were later determined. Animals were then heparinized (1000U/kg iv.), and the heart, right kidney, thoracic aorta and the gracilis anticus muscles were removed and placed into ice-cold modified Krebs buffer. Right kidney and heart wet weights were then determined.
Heme Oxygenase-1 ELISA
Thoracic aorta segments were removed as described above, snap frozen in liquid N 2 and stored at -70°C until analyzed. Aorta samples were powderized in liquid N 2 using a mortar and a pestle. Heme oxygenase-1 protein concentration was determined using the Stressgen rat heme oxygenase-1 ELISA kit (Stressgen, San Diego, CA) and protein concentration was determined using a micro BCA protein assay kit (Pierce Biotechnology, Inc., Rockford, IL). Heme oxygenase-1 content was expressed as ng of heme oxygenase-1 protein per mg of total protein.
Isolated Microvessel Experiments
Segments of first-order gracilis muscle arterioles were isolated by microdissection (45) and cannulated at both ends with glass micropipets in a vessel chamber (Living Systems Instrumentation, Burlington, VT). The vessel chamber was continuously superfused with gassed buffer (14% O 2 -5% CO 2 -balanced with N 2 ; 37°C) via a nonrecirculating system. For internal diameter measurements, the vessel chamber was mounted on a stage of an inverted microscope (Nikon TS 100-F) fitted with a CCD video camera. The camera was connected to a personal computer equipped with video dimensioning software (ImagePro Express, Media Cybernetics).
With this setup a magnified image of the arteriolar segment was performed on the computer monitor and internal diameter was measured by manually adjusting guides superimposed by the For experiments with no luminal flow, the proximal micropipet was connected to a pressure servo controller (Living Systems Instrumentation) and the distal micropipet to a closed stopcock to achieve and maintain 80mmHg constant luminal pressure with no flow. After a 60-minute stabilization period, the heme oxygenase inhibitor, 15µmol/l CrMP, or vehicle was included in the superfusion buffer 20min before the experiment. This treatment regime was continued throughout the experiment. After the pretreatment period, increasing concentrations of the endothelium-dependent vasodilator, acetylcholine (1nmol/l -3µmol/l) were added to the superfusion buffer. Each concentration was tested for 5 min, internal diameter was recorded every minute and the average of the last two measurements was used to determine the response.
To study flow-induced dilation, both the proximal and distal micropipets were connected to pressure servo controllers and an inline micro flowmeter (Living Systems Instrumentation).
The heme oxygenase inhibitor 15µmol/l CrMP alone, the heme oxygenase inhibitor and the heme oxygenase product carbon monoxide (mean system concentration 100µmol/l), or vehicle was included in the luminal perfusion buffer. During a 60-minute stabilization period, both proximal and distal pressures were adjusted to 80mmHg with no luminal flow. During the experiments, proximal and distal pressures were adjusted equally in opposite direction to maintain the midline pressure at 80mmHg and establish graded levels of luminal flow (0 -50µl/min in 5µl/min increments). Each flow was tested for 5 min, internal diameter was recorded every minute and the average of the last two measurements was used to determine the response.
Carbon monoxide concentration was determined at the inflow and outflow ports of the 
Statistics
All data are expressed as mean±SEM. Blood pressure and carbon monoxide excretion measurements, and vascular responses were analyzed by ANOVA using a computer statistical package (Sigma Stat 3.0). When significant differences were observed, orthogonal contrasts were performed as a post hoc analysis (44). All other data were analyzed by t tests, or when equal variance or normality tests failed by Mann-Whitney Rank Sum tests. A value of P<0.05 was considered statistically significant.
Results

Blood Pressure and Carbon Monoxide Excretion Measurements
Awake obese ZR had higher blood pressures (P < 0.05), respiratory carbon monoxide excretion rates (P < 0.05) and HbCO levels compared to lean ZR. In obese ZR rats administration of the heme oxygenase inhibitor ZnDPBG (25µmol/kg/day ip.) lowered mean arterial pressure without affecting heart rate ( Figure 1. panel A) . In obese ZR the heme oxygenase inhibitor ZnDPBG (25µmol/kg/day ip.) also lowered carbon monoxide excretion rates ( Figure 1. panel A) . In age matched lean ZR rats the heme oxygenase inhibitor did not affect blood pressure (Figure 1. panel B) , or carbon monoxide excretion rates (Figure 1. panel B) . Table 1 summarizes the body, kidney and heart weights of lean and obese ZR after 3 days of treatment with the heme oxygenase inhibitor, ZnDPBG (25µmol/kg/day ip.) or matched vehicle. Obese ZR had higher body weights, as well as kidney and heart weights compared to lean ZR. ZnDPBG treatment did not affect body or organ weights in either group. Table 2 summarizes metabolic parameters in lean and obese ZR after 3 days of treatment with the heme oxygenase inhibitor, ZnDPBG (25µmol/kg/day ip.) or matched vehicle. Nonfasting blood glucose, HbA1c, as well as insulin levels were higher in obese ZR compared to lean ZR, and ZnDBPG treatment did not affect these levels in either group. Total cholesterol and LDL cholesterol, but not HDL cholesterol levels were also higher in obese ZR. ZnDPBG treatment did not affect total or HDL cholesterol levels in either group. However, ZnDPBG treatment lowered LDL cholesterol levels in obese, but not in lean ZR. Oxidized LDL levels were also higher in obese ZR, and ZnDPBG did not affect these levels in either group.
Body and Organ Weight Measurements
Metabolic Parameters Measurements
Triglyceride levels were also elevated in obese ZR and exceeded the upper measurement limit of the Cardio Check PA meter in every case. ZnDPBG treatment did not significantly affect triglyceride levels in either group. 
Isolated Microvessel Experiments
First-order gracilis muscle arterioles isolated from obese ZR had larger passive internal diameters (lean: 198±4µm, n=14 versus obese: 210±3µm, n=21). During the 60-minute equilibration period diameters of both lean and obese ZR arterioles decreased spontaneously.
While the active internal diameters were larger in obese ZR arterioles (lean: 142±7µm versus obese: 159±4µm), there was no difference in myogenic tone between the two strains (lean: Δ max62±7µm versus obese: Δ max -56±4µm). Twenty-minute pretreatment with the heme oxygenase inhibitor, 15µmol/l CrMP, promoted similar vasoconstriction in both groups (lean: Δ max37±18µm versus obese: Δ max -40±4µm).
An endothelium-dependent vasodilator, acetylcholine (1nmol/l -3µmol/l) promoted concentration-dependent vasodilation in arterioles isolated from lean and obese ZR ( Figure 3 panel A). However, acetylcholine-induced vasodilation was greatly attenuated in obese ZR arterioles compared to the lean group (lean: Δ max 62±7µm; n=5 versus obese: Δ max 32±4µm; n=8; P < 0.05). Acute in vitro pretreatment with an inhibitor of heme oxygenase, 15µmol/l CrMP, 
Discussion
This study is the first to document that endogenous carbon monoxide production is increased in obese ZR with metabolic syndrome, and administration of a heme oxygenase inhibitor lowers respiratory carbon monoxide excretion, as well as blood pressure in awake, obese ZR. Endothelium-dependent vasodilator responses are decreased in skeletal muscle arterioles isolated from obese ZR. Furthermore, acute in vitro treatment with a heme oxygenase inhibitor restores endothelial function of resistance vessels to lean ZR levels, but exogenous carbon monoxide prevents these effects. These findings suggest that heme-derived carbon monoxide formation is increased in obese ZR with metabolic syndrome and contributes to hypertension and endothelial dysfunction of resistance vessels. Previous studies suggested that Due to a non-functional leptin receptor gene (19) , the obese ZR is a well established genetic model of obesity (58) and metabolic syndrome (29,13). Consistent with this, we found that obese ZR exhibit all elements of metabolic syndrome, such as increased body weight, elevated blood glucose, insulin, triglycerides, total, as well as LDL cholesterol levels, and hypertension. Metabolic syndrome represents a major risk factor for the development of type 2 diabetes. A previous study reported that patients with type 2 diabetes show increased respiratory carbon monoxide levels (39). Although the blood glucose levels in these obese ZR are not as high as in other experimental diabetes models, we did find that respiratory carbon monoxide excretion, as well as HbCO levels, is increased in obese ZR indicative of increased endogenous carbon monoxide formation.
The primary endogenous source of carbon monoxide formation is the enzymatic breakdown of heme by heme oxygenase (47). Our previous studies suggested that increased heme oxygenase-derived carbon monoxide formation contributes to salt-induced hypertension in 14 subsequent increase in sympathetic outflow (25). In the current study we chose a lower dose of ZnDPBG (25µmol/kg/24hr ip), which decreases respiratory carbon monoxide excretion (52), but minimizes central nervous system effects (52). We found that administration of a heme oxygenase inhibitor, ZnDPBG, reduced respiratory carbon monoxide excretion and lowered blood pressure in awake, obese ZR. These data suggest that increased heme oxygenase-derived carbon monoxide production might contribute to hypertension in obese ZR.
A potential mechanism by which the heme oxygenase inhibitor could lower the blood pressure in obese ZR is through the improvement of metabolic parameters. Although ZnDPBG treatment did lower LDL cholesterol levels in obese ZR, body weight, as well as the rest of the other metabolic parameters (blood glucose, HbA1c, plasma insulin, total cholesterol, HDL cholesterol, and triglycerides levels) were not significantly affected by the heme oxygenase inhibitor. These data argue against major metabolic mechanisms for the blood pressure lowering effect of heme oxygenase inhibition.
Our previous studies in Dahl salt-sensitive rats suggested that increased heme-derived carbon monoxide production contributes to salt-induced hypertension (48) by promoting endothelial dysfunction in resistance vessels (21,48). Decreased endothelium-derived nitric oxide-mediated vasodilation in skeletal muscle arterioles has been suggested to contribute to hypertension in obese ZR (12-14). Thus, we decided to examine if heme oxygenase-derived carbon monoxide contributes to arteriolar endothelial dysfunction in obese ZR. We similarly found that responses to an endothelium-dependent vasodilator, acetylcholine, were attenuated in first-order gracilis muscle arterioles isolated from obese ZR. While acetylcholine is widely used to assess nitric oxide-mediated endothelial function, previous studies suggested that pathological states can impair muscarinic receptor signaling proximal to nitric oxide synthase (46). An alternative method to circumvent this potential feature is to generate nitric oxide by increasing shear forces along the vascular endothelium. We found that skeletal muscle arterioles from obese ZR failed to dilate in response to flow. Since both acetylcholine and flow-induced (26) dilation can be abolished by nitric oxide synthase inhibition, these data suggest that obese ZR show impaired endothelium-dependent nitric oxide-mediated vasodilation.
To test whether heme oxygenase contributes to endothelial dysfunction in obese ZR we employed another inhibitor, CrMP. This metalloporphyrin is a selective (3) and photostable (51) inhibitor of heme oxygenase activity which was reported to decrease carbon monoxide formation in rat first-order gracilis muscle arterioles (57) . We found that acute in vitro application of this heme oxygenase inhibitor restored acetylcholine and flow-induced vasodilator responses in obese ZR and abolished the differences between lean and obese ZR arterioles. These data suggest that a vascular heme oxygenase product contributes to endothelial dysfunction in obese ZR.
Recent studies indicate the physiologically relevant concentrations of carbon monoxide (0.5-50µmol/l) (54,55) can inhibit nitric oxide synthase (37,56), promote endothelial nitric oxide synthase-dependent vasoconstriction (23,42) and impair endothelium-dependent vasodilation (49). We have previously reported that heme-derived carbon monoxide impairs flow-induced dilation in normotensive rat arterioles (26). We have now found that CrMP, a heme oxygenase inhibitor, restores flow-induced dilation in arterioles from obese ZR. To test whether heme oxygenase-derived carbon monoxide mediates endothelial dysfunction in obese ZR arterioles we employed simultaneous treatment with the heme oxygenase inhibitor and exogenous carbon oxide system after mechanical denudation of the endothelium (balloon injury, atherosclerosis, or experimental removal) or inhibition of nitric oxide synthesis like in our initial studies (32). Our current study does not address the potential benefits of increased heme oxygenase activity in the obese ZR, but rather clarifies that such benefits may be at least partially undermined by its tendency to promote endothelial dysfunction and hypertension.
We have avoided some common manipulations of the heme oxygenase system. Some Previous studies suggested two other major mechanisms for decreased endotheliumderived nitric oxide-mediated vasodilation in obese ZR arterioles. Oxidative stress has been documented in obese ZR (13), and it is suggested to promote endothelial dysfunction by directly chelating nitric oxide (13,14). However, oxidative stress is also a potent inducer of heme oxygenase-1 expression (2) and also promotes the formation of oxidized LDL (7), which can promote endothelial dysfunction (7), as well as induce heme oxygenase-1 expression (1). In the current study we found that plasma oxidized LDL levels are elevated in obese ZR. Therefore, the possibility exists that oxidative stress promotes endothelial dysfunction not just by direct chelation of nitric oxide, but also by increasing vascular heme oxygenase-derived carbon monoxide formation. The other major mechanism for decreased endothelium-derived nitric oxide-mediated vasodilation in obese ZR arterioles is mediated by the betaII isoform of protein kinase C (5,6). Recently, protein kinase C has been shown to increase heme oxygenase activity (4,34), as well as heme oxygenase-1 levels (34). Therefore, the possibility exists that part of the effects of protein kinase C on endothelial nitric oxide production are mediated by increased heme oxygenase-derived carbon monoxide production. Thus, our current results are not proposing an alternate mutually exclusive mechanism for endothelial dysfunction in obese ZR, but rather may identify a common mediator downstream from the other previously described mechanisms. This In summary, we found that endogenous carbon monoxide production is increased in obese ZR with metabolic syndrome and that administration of a heme oxygenase inhibitor to "normalize" carbon monoxide excretion lowers blood pressure in awake, obese ZR. In addition, we find that endothelium-dependent vasodilatory responses are decreased in skeletal muscle arterioles isolated from obese ZR. Furthermore, acute in vitro treatment with a heme oxygenase inhibitor restores endothelium-dependent dilation to lean ZR levels, but exogenous carbon monoxide prevents these effects. These findings suggest that heme-derived carbon monoxide formation is increased in obese ZR with metabolic syndrome and contributes to hypertension and endothelial dysfunction in resistance vessels. Our results may help to identify novel therapeutic targets to improve endothelial function and treat hypertension in patients with metabolic syndrome.
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